ROBERT NELSEN - 02 Jun 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: Director
Signature: /s/ Tyler Nielsen, by power of attorney
Issuer symbol: DNLI
Transactions as of: 02 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 04 Jun 2021, 18:35:30 UTC
Previous filing: 25 May 2021
Next filing: 16 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Award	$0	+2,074	+20%	$0.000000	12,432	02 Jun 2021	Direct	F1
holding	DNLI	Common Stock						9,668,749	02 Jun 2021	Held by ARCH Venture Fund VIII, L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNLI	Stock Option (right to buy)	Award	$0	+6,222		$0.000000	6,222	02 Jun 2021	Common Stock	6,222	$63.76	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2	The sole general partner of ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of ARCH VIII LLC and may be deemed to beneficially own the shares held by ARCH Fund VIII. Mr. Nelsen disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3	100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.